Psyence Biomedical Ltd. (NASDAQ:PBM) Sees Significant Decline in Short Interest

Psyence Biomedical Ltd. (NASDAQ:PBM) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 11,000 shares, a decline of 98.4% from the October 31st total of 671,900 shares. Based on an average daily volume of 104,900 shares, the short-interest ratio is presently 0.1 days. Approximately 1.8% of the shares of the company are sold short.

Institutional Trading of Psyence Biomedical

An institutional investor recently bought a new position in Psyence Biomedical stock. Virtu Financial LLC acquired a new stake in Psyence Biomedical Ltd. (NASDAQ:PBM) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,419 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned 0.30% of Psyence Biomedical as of its most recent SEC filing. Institutional investors own 77.44% of the company’s stock.

Psyence Biomedical Stock Up 5.1 %

Shares of NASDAQ PBM opened at $3.51 on Friday. The stock has a fifty day moving average price of $6.38 and a 200 day moving average price of $26.66. Psyence Biomedical has a 1-year low of $3.01 and a 1-year high of $323.25.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.